Novartis Presents Real-World Data Confirming Entresto Reduces Heart Failure Hospitalizations

Novartis today presented real-world evidence from multiple large observational studies including over 100,000 patients showing that Entresto (sacubitril/valsartan) significantly reduces heart failure hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) in clinical practice. The pooled analysis demonstrated a 25% reduction in heart failure hospitalizations compared to ACE inhibitors or ARBs. These real-world results are consistent with the pivotal PARADIGM-HF trial data and confirm the effectiveness of Entresto in routine clinical practice. Novartis continues to study sacubitril/valsartan in other heart failure populations.